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Abstract
Introduction: Previous research suggests patients with rheumatoid arthritis (RA) may receive suboptimal care with
respect to preventive tests and services. We evaluated the proportion of older Americans with RA, psoriatic arthritis
(PsA), and osteoarthritis (OA) receiving these services and the specialty of the providers delivering this care.
Methods: Using data from 1999 to 2006 from the Medicare Chronic Conditions Warehouse, we identified persons
age >/= 65 in the national 5% sample. Over the required five-year observation period, we identified tests and
services recommended for older adults and the associated healthcare provider. Services of interest included dual
energy x-ray absorptiometry (DXA), influenza and pneumococcal vaccination, hyperlipidemia lab testing,
mammography and colonoscopy.
Results: After accounting for the sampling fraction, we identified 141,140 RA, 6,300 PsA, and 770,520 OA patients
eligible for analysis. Over five years, a majority of RA, PsA, and OA patients were tested for hyperlipidemia (84%,
89% and 87% respectively) and received DXA (69%, 75%, and 52%). Only approximately one-third of arthritis
patients received pneumococcal vaccination; 19% to 22% received influenza vaccination each year. Approximately
20% to 35% of arthritis patients never underwent mammography and colonoscopy over five years. Concomitant
care from both a rheumatologist and a primary care physician was significantly associated with a greater likelihood
of receiving almost all preventive tests and services.
Conclusions: Among older Americans on Medicare, the absolute proportion of persons with arthritis receiving
various recommended preventive services and screening tests was substantially less than 100%. Improved co-
management between primary care and arthritis physicians may in part improve the delivery of preventive care for
arthritis patients, but novel systematic interventions in this area are needed.
Introduction
Providing preventive care for complex patients with
chronic medical problems is a challenging endeavor [1].
Poor quality of care for many chronic conditions such
as osteoporosis has been documented [2,3] despite the
availability of evidence-based guidelines and clear
recommendations for managing these conditions [4,5].
Recent efforts in the United States to promote high
quality care have raised awareness of adhering to evi-
dence-based national recommendations. Modest incen-
tives through the Medicare program provide further
motivation to provide certain preventive services [6].
Despite these recent trends that encourage high-qual-
ity care, previous research suggests that patients with
inflammatory arthritis such as rheumatoid arthritis (RA)
receive suboptimal preventive services and care for
concomitant comorbidities [7]. Disease and treatment-
related risk factors for adverse outcomes that are
associated with RA and other forms of inflammatory
arthritis such as psoriatic arthritis (PsA) make the need
for these services even more compelling than for the
average person or for individuals with non-inflammatory
arthritis such as osteoarthritis (OA). For patients with
inflammatory arthritis, biologic medications, non-biolo-
gic disease modifying anti-rheumatic drugs (DMARDs),
and other treatments that cause immunosuppression
(for example, long term glucocorticoid use) are asso-
ciated with a risk for infection that is increased
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partially mitigated with appropriate vaccination. RA is
also recognized as an independent risk factor for osteo-
porosis and fracture [10], making the need for bone
mineral density (BMD) testing using dual energy x-ray
absorptiometry (DXA) more compelling. Persons with
RA have an increased risk for certain malignancies such
as lymphoma although they have a slightly lower risk
for breast and colon cancer [11-14]. Rates of cardiovas-
cular events (for example, acute myocardial infarction)
[15-17] are higher in RA and PsA populations, and
these patients are recognized to need more aggressive
cardiovascular risk factor management than the general
population [18].
Despite the clear importance of these preventive ser-
vices and screening tests, identifying which of a patient’s
physicians should be responsible for providing these is
sometimes unclear. Primary care physicians may be
most well-versed and accustomed to providing these
services, yet arthritis specialists (for example, rheumatol-
ogists) may have more frequent contact with some of
these patients. Furthermore, some RA medications may
adversely affect risk factors for the conditions of interest
(for example, glucocorticoids on BMD, biologic medica-
tions on lipid profiles [19-24]), and rheumatologists pre-
scribing these may therefore have greater opportunity to
consider how these medications impact their patients’
various risk factors. Among many possible factors, a
lack of co-management between primary care and
arthritis specialists, poor between-provider communica-
tion about who should be responsible for providing pre-
ventive services and tests, and time pressures on office
visits to manage complex patients, may result in patients
failing to receive recommended care.
In light of the greater-than-average need to provide
most evidence-based preventive services and screening
tests to patients with RA and PsA, we used national
Medicare data to study the proportion of RA, PsA and
OA patients receiving recommended preventive care vis
av i snational recommendations for the general popula-
tion (Table 1). These recommendations advise that all
older patients (irrespective of whether or not they have
arthritis) receive the services of interest. We compared
RA and PsA patients to OA patients, in part used as an
internal control group. We selected OA as a comparator
condition in order to understand how patients with
inflammatory arthritis compared with a similar group of
Medicare-enrollees without inflammatory arthritis-
related disease and treatment-associated risk factors for
infection, fracture, malignancy, and cardiovascular
events. Furthermore, we evaluated the factors associated
with receipt of each of the services and tests of interest,
including the specialty of the physician providing the
service, to understand whether involvement of primary
care physicians in the management of comorbidities for
arthritis patients was associated with an increased likeli-
hood of patients receiving the recommended preventive
tests and services.
Materials and methods
Data source and study cohort
We obtained person-specific, longitudinal administrative
claims data from the Center for Medicare and Medicaid
(CMS) from 1999 to 2006 for a random 5% sample of
Medicare enrollees. Use of the data was governed by a
Data Use Agreement from CMS and approved by the
university institutional review board (IRB), which
granted a waiver of informed consent. The CMS files
used in the analysis included the Denominator, Inpati-
ent, Outpatient, and Carrier files. Physician specialty is
identified on each outpatient claim.
I no r d e rt oi d e n t i f yp e r s o n sw i t hR A ,P s A ,a n dO A ,
we required at least two ICD9 codes from physician
office-visits for these conditions (714.X, 696.0, 715.X)
within a 12-month baseline period using previously
described and validated algorithms [7,25,26]. In order to
assure that all eligible subjects had five years of follow-
up, this baseline year was required to be 1999, 2000 and
2001. This same year was also used to assess other cov-
ariates of interest. Following this baseline period, begin-
ning on January 1 of the next calendar year, all
individuals were required to have five years of continu-
ous Medicare part A + B, and the last date of observa-
tion (relevant for the 2001 cohort) was therefore 31
December 2006. Individuals enrolled in a Medicare
Advantage plan were excluded (generally 15% to 20% of
Medicare enrollees) because their administrative data is
typically incomplete. Each individual meeting ICD9
diagnosis criteria was assigned to a mutually exclusive
category in the hierarchy of PsA, RA, and then OA. The
amount of overlap between PsA and RA was low; 0.8%
of RA patients had a concomitant diagnosis of PsA.
Outcomes of interest
The primary outcomes of interest were receipt of pre-
ventive services of various types including dual-energy
x-ray absorptiometry (DXA), influenza and pneumococ-
cal vaccination, mammography, colonoscopy, and tests
to assess hyperlipidemia (administrative codes available
upon request). Patients were considered to have received
DXA, pneumococcal vaccination, colonoscopy, and test-
ing for hyperlipidemia if they received this test or ser-
vice at least once during the five-year observation
period. Mammography and influenza vaccination were
evaluated at more frequent intervals. Since the focus of
this analysis was on preventive testing and not manage-
ment of abnormal conditions once recognized, patients
were credited with having a test no more than once
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and literature specific to that service were used by the
investigators to identify the relevant ICD-9 and Current
Procedural Terminology (CPT) codes for inclusion.
Codes were reviewed for appropriateness by a profes-
sional medical coder.
Statistical analysis
Descriptive statistics were used to compare demo-
graphics, comorbidities, and health services utilization
(for example, number of outpatient physician visits,
number of hospitalizations) stratified by type of arthritis.
The proportion of individuals with each type of arthritis
receiving each service within the five-year follow-up per-
iod was shown descriptively. Logistic regression was
used to evaluate the relationship between the type of
arthritis (RA and PsA referent to OA) and receipt of
each of the services of interest. Because mammography
and influenza vaccination are recommended more often
than once every five years, ordinal regression was used
to evaluate mammography (0, 1, >/= 2) and influenza
vaccination (yearly) in categories. The proportionality
assumption of the ordinal regression was confirmed
qualitatively by using multinomial logistic regression
with all categories represented as nominal. The poten-
tially confounding variables that we adjusted for con-
formed to the Aday-Anderson framework [27], which
groups these as predisposing factors (for example, age,
gender, race), enabling factors (for example, rural/urban
residence, geographic region, median household income
defined by census block group, receipt of care from a
specialist), and need-based (for example, comorbidities,
long term care).
The specialty of the physicians providing each service
was also identified. Becauset h ep r i m a r yf o c u so ft h i s
analysis was whether primary care physicians or arthritis
specialists provided the services of interest, we evaluated
the proportion of patients with at least one service of
each type provided by a rheumatologist, a primary care
physician, both, or neither. For the analysis of the provi-
der specialty, claims with non-specific physician special-
ties (for example, a multi-group practice) were excluded
and reduced the number of persons eligible for analysis
by approximately 3.5%. All analyses were conducted
using SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
Characteristics of the individuals with RA, PsA, and OA
are shown in Table 2. As expected, more than two-
thirds of each of the arthritis cohorts was women, and a
majority was white. Approximately one-fourth of RA
and PsA patients did not have at least two visits with a
primary care physician. In contrast, most care for OA
patients was delivered by a primary care physician and
not a rheumatologist.
Table 3 shows the proportion of patients with each
type of arthritis receiving various services. A majority of
women received DXA (69.2% with RA, 74.6% with PsA,
and 51.6% with OA). However, receipt of most other
services, irrespective of the type of arthritis, was sub-
stantially less than 100%. For example, only about 20%
of arthritis patients received annual influenza vaccina-
tion every year for each of the five years of observation.
Only one-third of arthritis patients received pneumococ-
cal vaccination at least once. Approximately 20% to 30%
of women with arthritis did not receive mammography
even once, and one-third of arthritis patients did not
undergo colonoscopy.
Table 4 shows the prevalence odds ratios for each of
the preventive services and tests comparing RA and PsA
patients to OA patients. As shown, RA and PsA patients
were more likely to receive DXA than OA patients. RA
Table 1 National recommendations for screening tests and immunizations
Agency Screening or immunization Interval for repeat testing
CDC Influenza vaccine for adults age 65 and older one dose every year in the fall or winter
CDC Pneumococcal polysaccharide for adults age 65 and older ￿ one dose if unvaccinated
￿ one-time revaccination at least five years after first dose if given
prior to age 65
USPTF Lipid screening for men age 35 and older Every five years; less or more often if warranted
USPTF Lipid screening for women age 45 and older if at increased risk
for heart disease
Every five years; less or more often if warranted
USPTF Breast cancer screening for women age 40 and older Every one to two years
USPTF Colorectal cancer screening for adults age 50 to 75 years old ￿ Annual screening with high-sensitivity FOBT
￿ Sigmoidoscopy every five years, with high-sensitivity FOBT every
three years
￿ Screening colonoscopy every 10 years
USPTF BMD testing - all women age 65 and older No specific interval recommended
NOF BMD testing - women age 65 and older, and men age 70 and
older
Every two years or more often if warranted
CDC, Center for Disease Control; NOF, National Osteoporosis Foundation; USPTF, US Preventive Services Task Force
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coccal vaccination but less likely to undergo cholesterol
testing or cancer screening.
Over the five-year observation period, among RA, PsA,
and OA patients who had at least one test or service
performed, the proportion who had the test or service
provided by a rheumatologist (with or without addi-
tional tests or services provided by a primary care physi-
cian) was 50.2%, 43.1%, and 17.5% for DXA; 17.7%,
14.5%, and 2.3% for at least one influenza vaccination;
9.6%, 6.9%, and 1.1% for pneumococcal vaccination; and
11.0%, 11.4%, and 1.8% for any hyperlipidemia lab test.
Physician specialty was further examined for RA patients
in Table 5, which described and controlled for addi-
tional factors associated with these services among RA
patients (insufficient numbers of PsA patients were
available within the data to permit analogous results).
As shown, older patients, African Americans, and those
with lower incomes were significantly less likely to
receive most preventive tests and services. Men were
more likely to be tested for hyperlipidemia. Higher
income was associated with receipt of all preventive
tests and services except for mammography, which var-
ied little across income groups. For DXA, care from a
rheumatologist, with or without concomitant care from
a primary care physician, was significantly associated
with receipt of DXA. In contrast, compared to care pro-
vided only by a rheumatologist, RA patients were signifi-
cantly more likely to receive all other preventive tests
and services if they had concomitant care from a pri-
mary care physician.
Discussion
Among older Americans with RA, PsA, and OA our
results show that over a five-year observation period,
important preventive tests and services such as influenza
and pneumococcal vaccination were substantially under-
utilized. Only 19% to 33% of arthritis patients received
these vaccinations as recommended. In contrast,
Table 2 Descriptive characteristics of older Medicare
enrollees with rheumatoid arthritis, psoriatic arthritis,
and osteoarthritis
Variable Rheumatoid
arthritis
N = 141,140
Psoriatic
arthritis
N = 6,300
Osteoarthritis
N = 770,520
Demographics
Age
65 to 69 32.5 39.4 23.9
70 to 74 31.2 31.8 27.1
75 to 84 22.3 18.7 25.4
85+ 10.4 8.3 15.0
Gender, %
Female 76.9 60.0 72.9
Male 23.1 40.0 27.1
Race, %
Asian 0.8 - 1.1
Black 6.4 - 7.7
Hispanic 1.6 - 2.0
Other 1.2 - 1.0
White 90.0 97.1 88.2
Rural/Urban, %
Urban Core 64.3 71.4 65.1
Not Urban Core 35.8 25.6 34.9
Geographic Region, %
Northeast 20.5 26.7 20.9
Midwest 26.1 21.9 24.6
West 14.9 13.3 14.8
South 38.5 38.1 39.6
Income in $, %
0 to - <30,000 20.0 13.7 22.5
30,000 to <45,000 39.4 34.0 38.3
45,000 to <60,000 22.3 22.2 21.2
60,000 to <75,000 10.5 14.6 9.7
75,000+ 7.8 15.6 8.3
Comorbidities, %
Myocardial infarction 2.5 - 2.5
Heart failure 5.6 3.5 6.4
Cardiovascular disease 4.1 5.4 5.4
Dementia 0.5 - 0.8
Chronic pulmonary
disease
14.1 11.8 13.4
Cancer (any) 6.7 7.6 7.6
Hypertension 37.1 42.2 49.0
Osteopenia 0.8 - 0.9
Osteoporosis 9.7 5.1 7.0
Closed hip fracture 0.8 - 0.7
Physician Specialty (≥2
visits), %
No rheumatology and
no primary care
6.5 5.1 18.9
Rheumatology but no
primary care
23.9 27.0 4.2
Primary care but no
rheumatology
30.9 21.6 68.4
Table 2 Descriptive characteristics of older Medicare
enrollees with rheumatoid arthritis, psoriatic arthritis,
and osteoarthritis (Continued)
Both Rheumatology
and primary care
38.7 46.4 8.5
Physician Visits, n 14.3 (0, 142) 15.2 (2, 64) 12.8 (0, 168)
Number of days of
inpatient hospitalization, n
2.2 (0, 365) 1.7 (0, 66) 3.0 (0, 348)
Receipt of any Long Term
Care, %
2.3 0.6 3.5
Data shown as % or as mean (range). All data were assessed in the 12-month
baseline period before the start of the five-year observation period.
Totals may not sum to exactly 100% due to rounding.
Cells with a “-"were suppressed due to requirements imposed by data use
agreement restrictions related to small cell sizes
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graphy, colonoscopy, DXA and hyperlipidemia lab test-
ing was better, ranging from 40% to 90%. Except for
DXA, rheumatologists provided few of these services;
more optimal use of preventive tests and services was
associated with concomitant care from both a primary
care physician and a rheumatologist. However, about
25% of patients with inflammatory arthritis did not have
concomitant care from a primary care physician.
Compared with the general population, influenza vac-
cination and breast cancer screening rates reported in
our study are lower than those reported by National
Committee for Quality Assurance (NCQA) using the
Health Plan Employer Date and Information Set
(HEDIS) data [2]. HEDIS data are annually obtained
from administrative claims, medical record review of a
random sample of eligible patients, or a combination of
both. The influenza vaccination rate from HEDIS in the
general population (69%) represents the percentage of
adults aged 65 and older who receiving an influenza
vaccination during the most recent flu season. The
breast cancer screening rate (67%) in HEDIS represents
the percentage of women 40 to 69 years who had a
mammogram to screen for breast cancer within the last
two years. The colonoscopy rates in our cohort are
higher than the colorectal cancer screening rate reported
in the HEDIS (50%), despite more liberal definitions
used by HEDIS which allow for any of the four
following tests: fecal occult blood test (FOBT) during
the measurement year, flexible sigmoidoscopy during
t h ep a s tf i v ey e a r s ,d o u b l ec o n t r a s tb a r i u me n e m a
during the five years, and colonoscopy during the past
10 years.
The proportion of arthritis patients with BMD mea-
surement in our study was higher than previously
reported for the general U.S. Medicare population age
>/= 65 years; in the general population, only about one-
third of women and <5% of men had received BMD
testing at any time over a seven-year period [28].
Because many rheumatologists have in-office DXAs and
bill for this service [28], they likely are more attuned to
providing DXA to their patients. We also found that the
performance rates were relatively high for hyperlipide-
mia screening (83% to 90%) compared with other pre-
ventive services. They were similar to the 81% to 88%
rates reported by NCQA and others [2]. This may be
due to there being fewer barriers to testing and ready
accessibility of hyperlipidemia lab testing to physicians
of all specialties, in contrast to other services such as
DXA and colonoscopy which require access to special
equipment or physicians with specialized training in per-
forming this procedure.
Interestingly, starting at approximately age 75, advancing
age was associated with a lower likelihood of receipt of
DXA, hyperlipidemia lab testing, and cancer screening,
Table 4 Adjusted* association between type of arthritis
and receipt of preventive services, referent to
osteoarthritis patients
Outcome variable Rheumatoid
arthritis
OR (95% CI)
Psoriatic
arthritis
OR (95% CI)
DXA 1.66(1.55, 1.77) 1.55(1.19, 2.02)
Vaccination
Influenza** 1.02(0.97, 1.07) 0.88(0.72, 1.07)
Pneumococcal Vaccine 1.11(1.05, 1.19) 1.04(0.82, 1.32)
Cholesterol lab testing 0.56(0.52, 0.61) 0.79(0.53, 1.18)
Cancer Screening Tests
Mammography (Women
Only)**
0.65 (0.60, 0.69) 0.81(0.59, 1.1)
Colonoscopy 0.83 (0.78, 0.88) 0.90(0.7, 1.16)
CI, confidence interval; OR, odds ratio.
Results in each column are referent to patients with osteoarthritis. Each row
represents a unique model.
* adjusted for demographic variables (age, gender, race, geographic region,
median household income, rural/urban), predisposing conditions (AMI, CHF,
peripheral vascular disease, cardiovascular disease, dementia, COPD, peptic
ulcer disease, diabetes with and without complications, paraplegia, chronic
kidney disease, cancer, severe liver disease, Alzheimers, hypertension,
osteopenia, osteoporosis), prior history of fractures (hip, ankle, clavicle, distal
radius/ulna, other radius/ulna, carpal bone, spine, tibia-fibula, humerus, femur,
pelvis), health services utilization (hospital days, number of physician visits,
days in long term care, physician specialty)
** odds ratios obtained using ordinal logistic regression, grouped as (0, 1, >/=
2) for mammography tests, and (0, 1, 2, 3, 4, 5) for number of annual
influenza vaccination
Table 3 Proportion of patients with rheumatoid,
psoriatic, and osteoarthritis receiving preventive services
during five years of follow-up
RA
N=
141,140
PsA
N=
6,300
OA
N=
770,520
DXA, % (Women) 69.2 74.6 51.6
DXA, % (Men) 36.7 28.6 10.2
Influenza vaccination, %
Not vaccinated 17.3 15.6 18.5
Only 1 vaccination 8.9 10.2 10.1
Only 2 vaccinations 11.6 13.0 11.9
Only 3 vaccinations 16.6 14.6 16.8
Only 4 vaccinations 24.0 27.9 22.9
Vaccinated all five years 21.6 18.7 19.8
Pneumococcal vaccination, % 33.0 33.0 29.0
Mammography, % (women
only)
None 29.2 20.1 28.2
Only 1 14.2 12.2 13.6
2 or more 56.6 67.7 58.2
Colonoscopy, % 64.8 70.5 64.8
Hyperlipidemia lab testing, % 83.5 88.9 87.1
Data shown as %
Totals may not sum to exactly 100% due to rounding
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vascular disease (CVD), and malignancy. This may be
related to a physician’s and patient’s lack of expectation of
benefit of these services, perhaps in relation to concern for
an offsetting mortality risk from other causes. However,
because our analysis intentionally included only indivi-
duals who remained alive and under observation for five
years, our analysis represents a healthier group of indivi-
duals with arthritis. For this reason, the preventive tests
and services we studied would seem to be even more
appropriate than for a less select population where offset-
ting mortality risk may attenuate the benefit of screening
tests. There are likely additional explanations for why
older patients were less likely to receive most preventive
Table 5 Factors associated* with preventive tests and services and among RA patients
DXA Influenza
vaccination
Pneumococcal
vaccination
Hyperlipidemia lab
testing
Mammography Colonoscopy
OR (95%
CI)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age
65 to 69 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
70 to 74 0.93 (0.81,
1.07)
0.96 (0.87, 1.07) 0.89 (0.78, 1.00) 0.72 (0.60, 0.86) 0.71 (0.61, 0.81) 1.07 (0.94,
1.21)
75 to 79 0.62 (0.54,
0.72)
1.02 (0.91, 1.14) 0.92 (0.80, 1.06) 0.62 (0.51, 0.74) 0.51 (0.44, 0.60) 0.75 (0.65,
0.86)
80 to 84 0.49 (0.40,
0.59)
1.00 (0.86, 1.16) 0.82 (0.68, 0.98) 0.36 (0.29, 0.44) 0.28 (0.23, 0.33) 0.73 (0.61,
0.87)
85+ 0.30 (0.22,
0.40)
0.96 (0.76, 1.21) 0.65 (0.48, 0.88) 0.25 (0.19, 0.35) 0.15 (0.11, 0.21) 0.49 (0.38,
0.65)
Gender
Female 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Male 0.22 (0.19,
0.25)
1.12 (1.01, 1.24) 0.99 (0.88, 1.12) 1.18 (1.00, 1.40) Women Only 0.99 (0.88,
1.12)
Race
White 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Asian 0.67 (0.37,
1.21)
1.11 (0.69, 1.79) 1.12 (0.63, 1.99) 1.52 (0.59, 3.91) 1.05 (0.90, 1.22) 0.75 (0.43,
1.32)
Black 0.58 (0.46,
0.72)
0.41 (0.34, 0.50) 0.95 (0.76, 1.19) 0.83, (0.63, 1.09) 1.06 (0.92, 1.22) 1.21 (0.97,
1.51)
Hispanic 0.74 (0.49,
1.11)
0.48 (0.34, 0.67) 0.68 (0.44, 1.07) 0.97 (0.57, 1.67) 1.12 (0.95, 1.33) 0.73 (0.50,
1.08)
Other 0.70 (0.44,
1.13)
0.51 (0.35, 0.75) 0.60 (0.35, 1.02) 0.67 (0.38, 1.17) 0.99 (0.87, 1.12) 0.83 (0.53,
1.30)
Income, $
0 to <30,000 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
30,000 to <45,000 1.07 (0.93,
1.24)
1.22 (1.09, 1.38) 1.16 (1.01, 1.34) 1.07 (0.90, 1.28) 0.99 (0.67, 1.49) 1.24 (1.08,
1.43)
45,000 to <60,000 1.43 (1.20,
1.69)
1.52 (1.33, 1.74) 1.19 (1.01, 1.40) 1.40 (1.13, 1.73) 0.61 (0.48, 0.79) 1.35 (1.15,
1.59)
60,000 to <75,000 1.15 (0.94,
1.42)
1.45 (1.22, 1.71) 1.25 (1.02, 1.53) 1.48 (1.12, 1.95) 0.83 (0.60, 1.16) 1.29 (1.06,
1.58)
75,000+ 1.28 (1.02,
1.62)
1.57 (1.30, 1.89) 1.28 (1.02, 1.60) 1.57 (1.14, 2.16) 0.92 (0.69, 1.23) 1.70 (1.35,
2.15)
Physicians providing care (≥2 visits)
Rheumatology but no
primary care
1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Both rheumatology and
primary care
1.05(0.91,
1.21)
1.71(1.53, 1.91) 1.21(1.05, 1.38) 1.28(1.07, 1.53) 1.41(1.21, 1.63) 1.35(1.18,
1.55)
Primary care and no
rheumatology
0.56(0.49,
0.65)
1.32(1.18, 1.48) 0.97(0.84, 1.11) 1.34(1.12, 1.6) 1.03(0.89, 1.2) 1.06(0.92,
1.21)
No rheumatology or
primary care
0.66(0.52,
0.83)
0.87(0.72, 1.05) 0.77(0.61, 0.98) 0.87(0.66, 1.13) 1.05(0.83, 1.35) 1.17(0.93,
1.46)
CI: confidence interval; OR: odds ratio
*adjusted for all factors listed for Table 4.
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ited access to care (potentially affected by arthritis-related
disability), and patients’ refusal in light of their own goals
and values [29].
Focusing particularly on RA, where more comparative
literature is available, our findings are consistent with
previous population based studies showing generally low
preventive health care and screening services delivered
to RA patients. In 2000, MacLean et al. have raised
awareness of the need for increased attention to preven-
tive care for patients with RA [7]. This study assessed
quality of various services that RA patients received for
their arthritis, comorbid diseases, and health care main-
tenance by using administrative insurance data over a
four-year period (1991 to 1995). The overall quality
score for health care maintenance, which included col-
orectal cancer screening (colonoscopy or barium enema
once every five years for persons over 50), breast cancer
screening (mammogram annually for women aged 50 to
70), and cervical cancer screening (Papanicolaou testing
every three years for women aged 50 to 70) among eligi-
ble RA patients was 42% [7]. Recently, Aizer et al.
reported [30] that over half of patients with RA partici-
pating in the Consortium of Rheumatology Researchers
of North America (CORRONA) registry had not
received BMD testing despite RA being recognized as an
independent risk factor for osteoporosis. Using clinical
data from a population-based cohort of patients with
RA in Rochester with a median follow-up time of 5.4
years, Kremer and colleagues examined the probability
of receiving various preventive medical services includ-
ing influenza vaccination (once a year for persons over
65), pneumococcal vaccination (one time for persons
over 65), mammograms (biennially for ages 40 to 49
and annually for those 50 and over), and a lipid profile
(once every five years). Complete medical records were
reviewed by trained abstractors using a standardized
protocol with predefined variables. In this cohort, the
proportion of RA patients receiving influenza vaccina-
tion, pneumococcal vaccination, mammograms, and
lipid screening were 32%, 38%, 68%, and 88%, respec-
tively [31]. Similar to our results showing that only a
small minority of patients receive hyperlipidemia lab
testing from rheumatologists, a large not-for-profit
health system found that only 2% of these lab tests were
ordered by a rheumatologist [32]. Outside of the U.S.,
several additional studies have reported 36% to 81%
influenza and 34% to 54% pneumococcal vaccination
rates in patients with RA obtained from self-report,
patient survey, and/or chart audit, figures which were
largely derived from cross-sectional analyses in hospital-
based clinic settings [33-39].
In light of gaps in the use of preventive tests and ser-
vices we identified for arthritis patients, what can be
done to ameliorate this problem? A number of strategies
to improve quality of care in rheumatology have been
proposed and tested within the boundaries of traditional
care processes, with mixed results [40]. Simple interven-
tions involving educating providers via continuing medi-
cal education (CME) generally do not change physician
behavior or practice [41]. More intensive strategies
involving audit and feedback and academic detailing
have sometimes been more efficacious [42-45], but effect
sizes are often small. Our data suggested better co-man-
agement between primary care physicians and rheuma-
tologist might in part improve quality of care. This
might be facilitated, for example, by having the arthritis
specialists’ electronic health record (EHR) notes be gen-
erated in real-time and made available (either electroni-
cally, or via paper) to the primary care physician, either
via electronic exchange (EHR, or facsimile) or hand-car-
ried by the patient [32]. These notes could clearly
delineate the patients’ health maintenance and preven-
tive services needs and propose the provider responsible
for ensuring these services are ordered. At the present,
h o w e v e r ,e l e c t r o n i ch e a l t hr e c o r d sa r eu s e db yo n l ya
minority of physicians, and EHRs are rarely interoper-
able. Another potential opportunity may lie in better
engaging patients in their own care through use of new
personal health records (PHR), which enables patients
to better document and perhaps be better advocates for
their own healthcare. In light of these emerging infor-
mation technologies and an increasing focus on quality
of care for arthritis patients (at least related to the man-
agement of arthritis), new strategies need to be designed
and tested to optimize preventive care delivery [46]. It is
likely that achieving optimal preventive services in these
disease populations will require a shift from fragmented,
loosely-defined traditional care to system-based inter-
disciplinary care of patient populations with better
defined provider roles, nurse coordination of care, dis-
ease registries, and continuous quality improvement
methods [47].
The strengths of our study include evaluation of the
entire U.S. Medicare fee-for-service population and thus
our results have high generalizability. Unlike many man-
aged care plans with high turnover, patients typically do
not disenroll from Medicare, thus allowing us to have a
longer period of follow-up (five years, plus a one-year
baseline assessment period) than available in most other
health plans. Despite these strengths, our results must
be interpreted in light of the study design. It is possible
that some services such as influenza vaccination were
not billed to Medicare and were provided by another
agency (for example, a public health department).
Patients might also have been offered these services but
declined for a variety of reasons in light of their own
preferences and values. Another potential reason for a
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copayment, a hypothesis supported by our finding that
patients with higher income are more likely to receive
these services, with the notable exception of mammo-
graphy. Additionally, we recognize that the optimal
interval for repeating some tests (for example, DXA) is
not well-specified, particularly if a previous test was nor-
mal. However, except for colonoscopy, where testing is
recommended at least every 10 years, our observation
period of five years would seem long enough such that
at least one test or service of each type should have
been provided.
Conclusions
Based upon recommendations from national guidelines
applicable to the general U.S. population, patients with
arthritis generally received less than optimal care with
respect to receipt of preventive tests and services.
Although RA patients were more likely to receive BMD
testing, they were significantly less likely to receive eva-
luation for hyperlipidemia or screening for malignancy
compared to OA patients. Based upon higher rates and
risk factors for adverse events (for example, serious
infections, fracture, malignancy, and CVD among
patients with inflammatory arthritis, the need for the
preventive tests and services we studied is generally
more compelling for RA and PsA patients than for
patients with OA or the general population. Improved
co-management between primary care physicians and
arthritis specialists is likely to help improve the quality
of preventive care for arthritis patients. However, even
for patients who had both a rheumatologist and primary
care physician, rates of preventive services were less
than recommended. New cost-effective, and generaliz-
able interventions to systematically improve the delivery
of preventive care are needed, especially for patients
with inflammatory arthritis.
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